Oslo, Norway, September 04, 2023: NEC OncoImmunity (NOI), a leading artificial intelligence (AI) company, today has announced its participation in 21^st Awaji International Forum on Infection and Immunity held from September 03- September 06, 2023 at Karuizawa. NOI uses its cutting-edge AI technology to develop vaccines designs for several infectious diseases.

The poster presentation and oral presentation at this forum will be based on broadly protective, B and T cell vaccines against betacoronaviruses, T-cell based dengue fever vaccines, bioinformatic findings on Orthopoxvirus genus. The conference will be attended by delegates from NEC OncoImmunity.

Details and the time of presentation are as follows: See here for photos of the presentation.

Presentation Title: The design of broadly protective B cell and T cell betacoronavirus vaccines using artificial intelligence

• Presentation Type: Oral, S02-4
• Presenter: Dr. Trevor Clancy
• Session Title: Neovaccinology
• Date: September 3, 2023
• Time: 14:45-16:30 JST

Presentation Title: The design of broadly protective B cell and T cell betacoronavirus vaccines using artificial intelligence

• Presentation Type: Poster P06; Abstract No. 10045
• Presenter: Dr. Trevor Clancy
• Session Title: Vaccinology
• Date: September 5, 2023
• Time: 13:50-14:50 JST

Presentation Title: Towards the artificial intelligence design of universal T cell-based dengue fever vaccines

• Presentation Type: Poster P29; Abstract No. 10047
• Presenter: Dr. Sebastian Kapell
• Session Title: Virology
• Date: September 4, 2023
• Time: 14:10-15:10 JST

Presentation Title: A bioinformatics analysis demonstrates T cell correlates of protection against the entire Orthopoxvirus genus

• Presentation Type: Poster P14; Abstract No. 10046
• Presenter: Dr. Trevor Clancy
• Session Title: Virology
• Date: September 5, 2023
• Time: 13:50-14:50 JST

About NEC OncoImmunity
NEC OncoImmunity AS is an AI driven biotechnology company that has developed proprietary machine learning-based software which addresses the key knowledge gaps in the prediction of bona fide immunogenic neoantigens for personalized cancer immunotherapy. The AI technology can be used to identify optimal neoantigen targets for truly personalized cancer vaccines & cell therapies in a clinically actionable timeframe, and also facilitate effective patient selection for cancer immunotherapy. The AI technology has also been repurposed to identify optimal antigens from pathogens for the purpose of designing broadly protective vaccines against highly diverse viral species and viral genera, that are effective in the global population. For additional information, please also visit NEC OncoImmunity at
https://www.oncoimmunity.com/

Contact